On Friday, Shares of Apple Inc. (NASDAQ:AAPL), lost -1.10% to $127.17, as consumer stocks were moderately lower Friday, with shares of consumer staples companies in the S&P 500 falling 0.5% while shares of consumer discretionary firms in the S&P 500 were sliding 0.3%.
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Citizens Financial Group, Inc. (NYSE:CFG), inclined 0.07% to $27.54, during its last trading session.
Keefe, Bruyette & Woods, Inc., a full‐service, boutique investment bank and broker‐dealer that specializes in the financial services sector, and a wholly owned partner of Stifel Financial Corp. (SF), declared the forthcoming index rebalancing for second quarter of 2015. As part of this rebalancing, below are the component level changes across various indices:
KBW Bank Index (Index Ticker: BKX, ETF Ticker: KBWB):
Add: Citizens Financial Group, Inc. (CFG)
Delete: Commerce Bancshares, Inc. (CBSH)
KBW Regional Banking Index (Index Ticker: KRX; ETF Ticker: KBWR)
Add: Commerce Bancshares, Inc. (CBSH)
Delete: City National Corp. (CYN)
These changes will be effective preceding to the opening of business on Monday, June 22, 2015.
Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, N.A. and Citizens Bank of Pennsylvania that provide retail and commercial banking products and services in the United States. It operates through two segments, Consumer Banking and Commercial Banking.
Finally, Boston Scientific Corporation (NYSE:BSX), ended its last trade with -1.40% loss, and closed at $17.56.
On June 4, Boston Scientific Corporation, declared the European launch of the Precision Novi™ Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device presently accessible. The improved shape of the Precision Novi implant is designed to provide a new level of comfort to patients with pain treated using primary cell therapy. Precision Novi is powered by Illumina 3D™ Software that enables physicians to target pain precisely with point-and-click simplicity.
Chronic pain can have a devastating impact on quality of life for many patients. Spinal cord stimulators alleviate pain by stimulating the nerve fibers in the spinal cord to reduce pain signals. While primary cell (also referred to as non-rechargeable) devices are typically larger due to limitations in technology and battery size, the Precision Novi System represents a noteworthy technology advance, with the smallest high-capacity battery on the market, allowing effective pain relief to be delivered from a much smaller device. The Precision Novi System is also the only primary cell device that couples with a wireless remote , empowering patients with flexibility and control over their pain administration.
“The small size and novel shape of the Precision Novi implant improves patient comfort and enables a very discreet subcutaneous placement,” said Dr. Simon Thomson, a consultant in Pain Administration and Neuromodulation at Basildon and Thurrock University Hospitals, UK. “The simplicity of the programming software saves valuable time in the operating theatre, efficiently allowing me to achieve and maintain comfortable therapy for my patients.”
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
